These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38318544)

  • 41. Change in metacognitions predicts outcome in obsessive-compulsive disorder patients undergoing treatment with exposure and response prevention.
    Solem S; Håland AT; Vogel PA; Hansen B; Wells A
    Behav Res Ther; 2009 Apr; 47(4):301-7. PubMed ID: 19203749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cognitive-Behavioral Therapy Versus Transcranial Direct Current Stimulation for Augmenting Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder Patients.
    Dadashi M; Yousefi Asl V; Morsali Y
    Basic Clin Neurosci; 2020; 11(1):111-120. PubMed ID: 32483481
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Further psychometric properties of the Yale-Brown Obsessive Compulsive Scale - Second Edition.
    Wu MS; McGuire JF; Horng B; Storch EA
    Compr Psychiatry; 2016 Apr; 66():96-103. PubMed ID: 26995242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The suicidality continuum in a large sample of obsessive-compulsive disorder (OCD) patients.
    Velloso P; Piccinato C; Ferrão Y; Aliende Perin E; Cesar R; Fontenelle L; Hounie AG; do Rosário MC
    Eur Psychiatry; 2016 Oct; 38():1-7. PubMed ID: 27606439
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of an interview-only version of the Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS) in treatment-seeking youth with obsessive-compulsive disorder.
    Cervin M; Perrin S; Olsson E; Claesdotter-Knutsson E; Lindvall M
    Psychiatry Res; 2019 Jan; 271():171-177. PubMed ID: 30481695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psychache and Suicidal History in Patients with Obsessive-Compulsive Disorder.
    Demirkol ME; Namlı Z; Eriş Davul Ö; Karaytuğ MO; Tamam L; Yılmaz H
    Neuropsychiatr Dis Treat; 2019; 15():3531-3539. PubMed ID: 31920313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of symptom dimensions for obsessive compulsive disorder and obsessive compulsive-related disorders.
    Say Öcal D; Özdel K; Şafak Y; Kekilli Karnaz Y; Kısa C
    PLoS One; 2019; 14(7):e0218955. PubMed ID: 31276509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sex differences in the phenotypic expression of obsessive-compulsive disorder: an exploratory study from Brazil.
    Torresan RC; Ramos-Cerqueira AT; de Mathis MA; Diniz JB; Ferrão YA; Miguel EC; Torres AR
    Compr Psychiatry; 2009; 50(1):63-9. PubMed ID: 19059516
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Personality Beliefs in Obsessive-Compulsive Disorder: How Are They Related to Symptom Severity?
    Kart A; Yucens B
    Psychiatry Investig; 2020 Aug; 17(8):822-828. PubMed ID: 32750759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dysfunctional Metacognitive Beliefs in Patients With Obsessive-Compulsive Disorder and Pattern of Their Changes Following a 3-Month Treatment.
    Kim ST; Park CI; Kim HW; Jeon S; Kang JI; Kim SJ
    Front Psychiatry; 2021; 12():628985. PubMed ID: 33967851
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment response, symptom remission, and wellness in obsessive-compulsive disorder.
    Farris SG; McLean CP; Van Meter PE; Simpson HB; Foa EB
    J Clin Psychiatry; 2013 Jul; 74(7):685-90. PubMed ID: 23945445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Executive Functions of Obsessive Compulsive Disorder and Panic Disorder Patients in Comparison to Healty Controls.
    Kurt E; Yildirim E; Topçuoğlu V
    Noro Psikiyatr Ars; 2017 Dec; 54(4):312-317. PubMed ID: 29321703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in compulsion and anxiety symptoms with nicotine transdermal patches in non-smoking obsessive-compulsive disorder patients.
    Salín-Pascual RJ; Basañez-Villa E
    Rev Invest Clin; 2003; 55(6):650-4. PubMed ID: 15011734
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Performance of clinician versus self-report measures to identify obsessive-compulsive disorder in children and adolescents.
    Stewart SE; Ceranoglu TA; O'Hanley T; Geller DA
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):956-63. PubMed ID: 16379516
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcome of Intensive Cognitive Behaviour Therapy in a Residential Setting for People with Severe Obsessive Compulsive Disorder: A Large Open Case Series.
    Veale D; Naismith I; Miles S; Childs G; Ball J; Muccio F; Darnley S
    Behav Cogn Psychother; 2016 May; 44(3):331-46. PubMed ID: 26122913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Internet-Based Cognitive Behavioral Therapy With Real-Time Therapist Support via Videoconference for Patients With Obsessive-Compulsive Disorder, Panic Disorder, and Social Anxiety Disorder: Pilot Single-Arm Trial.
    Matsumoto K; Sutoh C; Asano K; Seki Y; Urao Y; Yokoo M; Takanashi R; Yoshida T; Tanaka M; Noguchi R; Nagata S; Oshiro K; Numata N; Hirose M; Yoshimura K; Nagai K; Sato Y; Kishimoto T; Nakagawa A; Shimizu E
    J Med Internet Res; 2018 Dec; 20(12):e12091. PubMed ID: 30559094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blood levels of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha and cognitive functions in patients with obsessive compulsive disorder.
    Karagüzel EÖ; Arslan FC; Uysal EK; Demir S; Aykut DS; Tat M; Karahan SC
    Compr Psychiatry; 2019 Feb; 89():61-66. PubMed ID: 30594753
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders: recruitment, assessment instruments, methods for the development of multicenter collaborative studies and preliminary results.
    Miguel EC; Ferrão YA; Rosário MC; Mathis MA; Torres AR; Fontenelle LF; Hounie AG; Shavitt RG; Cordioli AV; Gonzalez CH; Petribú K; Diniz JB; Malavazzi DM; Torresan RC; Raffin AL; Meyer E; Braga DT; Borcato S; Valério C; Gropo LN; Prado Hda S; Perin EA; Santos SI; Copque H; Borges MC; Lopes AP; Silva ED;
    Braz J Psychiatry; 2008 Sep; 30(3):185-96. PubMed ID: 18833417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.